Sigilon Therapeutics, Inc.·4

Mar 1, 4:41 PM ET

Pontes Josias 4

4 · Sigilon Therapeutics, Inc. · Filed Mar 1, 2023

Insider Transaction Report

Form 4
Period: 2023-02-28
Pontes Josias
VP, Head of Finance
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-02-28+140,000140,000 total
    Exercise: $1.09Exp: 2033-02-27Common Stock (140,000 underlying)
Footnotes (1)
  • [F1]The options vest as to 25% of the underlying shares of common stock on February 28, 2024, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the options are fully vested.

Documents

1 file
  • 4
    form4-03012023_090358.xmlPrimary